Jefferies downgrades Genmab recommendation due to lack of short-term catalysts
A lack of short-term catalysts is one of the reasons that investment bank Jefferies has changed its recommendation for Genmab stock. The biotech company's share price increase since the start of the year is another reason, as S&P's biotech index has fallen during the same period.
BY MARKETWIRE, TRANSLATED BY CATHERINE BRETT
US-based investment bank Jefferies has downgraded its recommendation for Genmab from "buy" to "hold," as the share price has risen by around 10 percent since the start of the year and 40 percent since March, while S&P's index has fallen 9 percent since the New Year.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Horizon begins phase four clinical trial of Genmab drug
For subscribers
